1 The retractions came only months after BioMed Central.

Though many editors dislike this practice Even, it is frequently used, for a true number of reasons. One is definitely that in specific fields, authors could be ideal qualified to suggest suitable reviewers for the manuscript and topic involved. Another is normally that it makes life easier for editors: finding suitable peer reviewers who are willing to review in a timely manner can be both tough and frustrating. A third reason could be that journals and publishers are multinational increasingly.Lyrica Pfizer’s total ad spending for Lyrica in 2014 was split evenly between your drug’s 2 indications: fibromyalgia and diabetic neuropathy . Lyrica is a preferred non-opioid choice for both neuropathic and nociceptive pain patients. The drug generated $5.2 billion in sales this past year and is ranked last on the top 10 set of best-selling brand-name medicines so far in 2015. Continue Reading >> 3. Eliquis Bristol-Myers Squibb and Pfizer’s Eliquis is one of the last entrants to the brand new oral anticoagulants class. Eliquis was originally accepted to reduce the risk of stroke and systemic embolism in sufferers with nonvalvular atrial fibrillation, though it received extra indications in 2014 to treat deep vein thrombosis and pulmonary embolism. The majority of the $219 million spent on marketing Eliquis was directed toward TV spots focused squarely on discrediting the older-generation blood slimmer warfarin.